CrizotinibDevelopment of resistance in lung adenocarcinoma: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2015年 / 1539卷 / 1期

关键词：

D O I：

10.1007/s40278-015-7663-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：108 / 108

相关论文

共 50 条

[41] GefitinibDrug resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2022, 1905 (1) : 220 - 220
[42] AntineoplasticsAcquired resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2019, 1756 (1) : 42 - 42
[43] NivolumabAcquisition of resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2018, 1711 (1) : 219 - 219
[44] AntineoplasticsDevelopment of resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2019, 1737 (1) : 39 - 39
[45] ErlotinibAcquired resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2018, 1698 (1) : 148 - 148
[46] ErlotinibDevelopment of resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2018, 1725 (1) : 144 - 144
[47] CrizotinibDevelopment of resistance during treatment for non-small cell lung cancer: case report
[J]. Reactions Weekly, 2017, 1666 (1) : 91 - 91
[48] Alectinib/ceritinib/crizotinibDevelopment of resistance and gastrointestinal toxicity: case report
[J]. Reactions Weekly, 2020, 1789 (1) : 19 - 19
[49] CrizotinibDevelopment of crizotinib resistance leading to disease progression: case report
[J]. Reactions Weekly, 2016, 1621 (1) : 83 - 83
[50] OsimertinibDevelopment of drug resistance in lung adenocarcinoma: case report
[J]. Reactions Weekly, 2020, 1809 (1) : 199 - 199

← 1 2 3 4 5 →